Growblox Sciences Inc (OP: GBLX )
0.0775 USD UNCHANGED Streaming Delayed Price Updated: 3:58 PM EST, Mar 1, 2021 Add to My Watchlist
Press releases about Growblox Sciences Inc
North American Spending on Legal Cannabis is Expected to Grow to USD 47 Billion by 2027
October 04, 2018
GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds
October 02, 2018
GB Sciences, Inc. (OTCQB: GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece. Titled: The...
GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization
October 01, 2018
GB Sciences, Inc. (OTCQB: GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)'s decision to reschedule GW Pharmaceuticals' Epidiolex, from...
Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
September 25, 2018
GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products,...
Jobs and Salaries in the Legal Cannabis Industry Continues to Grow
September 25, 2018
GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals
September 24, 2018
The new license provides access to the largest growing sectors in the cannabis industry. Multiple new brands for both medical and recreational markets being prepped for retail sales.
GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"
September 19, 2018
GB Sciences, Inc. (OTCQB:GBLX) has mobilized cannabis industry thought leaders to discuss both the immense potential for cannabis-based therapies and the challenges of delivering on their medical...
CannabisNewsAudio – Earth Science Tech, Inc. (ETST) at the Vanguard of the Cannabinoid Therapeutics Surge
September 18, 2018
GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary
September 18, 2018
GB Sciences, Inc. (OTCQB: GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research...
Data Shows the Global Medical Cannabis Usage Continues to Grow
September 11, 2018
The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
August 22, 2018
GB Sciences, Inc. (OTCQB:GBLX) With the first cannabis crop now in production at their high-tech 36,000 square-foot grow facility in Baton Rouge, teams from GB Sciences and the LSU AgCenter are working...
Robust Growth in Cannabidiol (CBD) and Hemp Market Fueling Strong Optimistic Outlook
August 21, 2018
GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop
August 20, 2018
GB Sciences, Inc. (OTCQB: GBLX) and the LSU Agricultural Center (LSU AgCenter), have now commenced operation in the environmentally controlled grow pod. The first plants in production were developed...
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
August 15, 2018
For the three months that ended June 30, 2018, GB Sciences, Inc. (OTCQB: GBLX) reported revenue of $1,315,284 and gross profit of $734,719. This compares to revenue and gross profit of $69,100 and...
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
August 05, 2018
GB Sciences, Inc. (OTCQB: GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski...
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
August 01, 2018
GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which...
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
July 30, 2018
The new Chief Compliance Officer Program and the SCORE App lay a solid compliance foundation to support GB Sciences’ rapidly maturing expansion plans.
GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
July 15, 2018
GB Sciences, Inc. (OTCQB: GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD,...
Demand for Cannabis Business Education Is Intensifying
July 09, 2018
Corporate strategy dedicated to scientific medical research, a viable drug development pipeline and a strong Intellectual Properties Patent Portfolio are cited as the key differentiating factors.
GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain
June 26, 2018
GB Sciences’ novel therapeutic approach paves the way for the creation of precision medicines derived from the cannabis plant.